Ironwood Pharmaceuticals (NASDAQ:IRWD) Stock Price Passes Above 200 Day Moving Average – Should You Sell?

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD)’s stock price passed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $3.89 and traded as high as $4.36. Ironwood Pharmaceuticals shares last traded at $4.30, with a volume of 3,500,427 shares traded.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on the company. Wall Street Zen raised Ironwood Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Sunday, May 17th. Weiss Ratings reissued a “sell (d+)” rating on shares of Ironwood Pharmaceuticals in a report on Monday, April 27th. One equities research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Ironwood Pharmaceuticals presently has an average rating of “Hold” and a consensus target price of $6.23.

Ironwood Pharmaceuticals Price Performance

The stock has a market capitalization of $671.80 million, a P/E ratio of 6.87 and a beta of 0.25. The stock has a fifty day moving average price of $3.82 and a 200 day moving average price of $3.90.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last issued its earnings results on Thursday, May 7th. The biotechnology company reported $0.24 EPS for the quarter, missing the consensus estimate of $0.25 by ($0.01). Ironwood Pharmaceuticals had a negative return on equity of 39.65% and a net margin of 28.26%.The company had revenue of $106.51 million during the quarter, compared to the consensus estimate of $92.11 million. Research analysts anticipate that Ironwood Pharmaceuticals, Inc. will post 1.04 earnings per share for the current year.

Insiders Place Their Bets

In related news, Director Julie Mchugh sold 21,571 shares of the company’s stock in a transaction that occurred on Tuesday, June 16th. The shares were sold at an average price of $3.73, for a total transaction of $80,459.83. Following the sale, the director owned 250,749 shares of the company’s stock, valued at approximately $935,293.77. This represents a 7.92% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Company insiders own 9.30% of the company’s stock.

Hedge Funds Weigh In On Ironwood Pharmaceuticals

Several hedge funds and other institutional investors have recently added to or reduced their stakes in IRWD. Integrated Wealth Concepts LLC raised its holdings in shares of Ironwood Pharmaceuticals by 21.4% in the 3rd quarter. Integrated Wealth Concepts LLC now owns 19,295 shares of the biotechnology company’s stock valued at $25,000 after acquiring an additional 3,406 shares in the last quarter. LSV Asset Management purchased a new position in shares of Ironwood Pharmaceuticals during the fourth quarter worth about $30,000. Captrust Financial Advisors purchased a new position in shares of Ironwood Pharmaceuticals during the second quarter worth about $32,000. Jump Financial LLC bought a new position in shares of Ironwood Pharmaceuticals in the fourth quarter worth approximately $34,000. Finally, DGS Capital Management LLC bought a new position in shares of Ironwood Pharmaceuticals in the fourth quarter worth approximately $35,000.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals, Inc is a commercial‐stage biotechnology company focused on the discovery, development and commercialization of medicines for gastrointestinal (GI) disorders. The company’s flagship product is linaclotide, marketed under the brand name LINZESS in the United States for the treatment of irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC). Through a strategic collaboration with Allergan (now part of AbbVie), Ironwood also commercializes linaclotide in select ex-U.S.